TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Nyxoah ( (NYXH) ) has issued an announcement.
On September 23, 2025, Nyxoah SA announced the expansion of its commercial presence in the Middle East, following the first successful Genio® implant in Abu Dhabi earlier in the year. The company is partnering with healthcare institutions in Dubai, Kuwait, and Abu Dhabi to broaden access to its Genio system, a unique treatment for Obstructive Sleep Apnea (OSA). This expansion is part of Nyxoah’s strategy to enhance its market position and improve patient outcomes in a region known for its advanced healthcare systems.
The most recent analyst rating on (NYXH) stock is a Buy with a EUR14.50 price target. To see the full list of analyst forecasts on Nyxoah stock, see the NYXH Stock Forecast page.
More about Nyxoah
Nyxoah is a medical technology company focused on developing and commercializing innovative solutions for Obstructive Sleep Apnea (OSA). Its primary product, the Genio system, is a leadless and battery-free hypoglossal neurostimulation therapy designed to treat moderate-to-severe OSA, a common sleep disorder associated with increased mortality risk and cardiovascular issues.
Average Trading Volume: 68,923
Current Market Cap: €159.1M
For a thorough assessment of NYXH stock, go to TipRanks’ Stock Analysis page.